BOSTON, Aug. 6, 2024
/PRNewswire/ -- Dotmatics, a leader in R&D scientific software
connecting science, data, and decision-making, today announced a
significant minority investment in BioGlyph, a startup biotech
software company that is developing technology to visually
illustrate, register, and model biologic molecules including,
specifically, multispecific antibodies (MsAbs).
BioGlyph possesses proprietary technology and exceptional talent
in the realm of MsAbs R&D focused on accelerating and improving
the development of protein therapeutics. One of the fastest growing
new research modalities today is MsAbs, and Dotmatics is supporting
its customers who are pursuing new therapies using a multimodal
approach to life science discovery.
MsAbs bind two or more antigens, enabling new therapeutic
applications that conventional monoclonal antibodies cannot
fulfill. This technology is crucial for bridging different cells or
receptor proteins on the same cell, presenting groundbreaking
opportunities in therapeutic development.
"This investment aligns with the repeated interest we are
hearing from customers about the need for software that supports
MsAb formats," said Thomas Swalla,
CEO of Dotmatics. "As drug discovery becomes more
multidisciplinary, the legacy software in labs isn't keeping pace
with new modalities. That's why we introduced our new scientific
intelligence platform, Luma, which lets scientists connect old and
new science in a way that enhances the precision and efficiency of
antibody design and production."
BioGlyph is led by CEO and co-founder Fernando Garces, formerly director of Protein
Therapeutics at Gilead Sciences and principal scientist at Amgen,
and BioGlyph founder McClain
Kressman, a PhD candidate at the University of California, Santa Cruz. Avi Peltz is also a co-founder and leads
software development at BioGlyph.
"After 20 years in protein engineering, I recognized that
traditional tools couldn't keep up with the increasing complexities
of biotherapeutics, especially MsAbs. This led the BioGlyph team to
create a visual software solution that empowers protein engineers
with creativity while managing registration, data labeling, and
in-silico testing of MsAbs' fitness, among other functions," said
Fernando Garces, CEO of BioGlyph.
"Our software will empower the R&D scientists to make better
decisions that accelerate timelines and lower costs. Working
together with Dotmatics will help us bring this in-demand
technology to market in an expedited way and one that explores many
avenues of integration with Dotmatics' industry-leading
technologies."
"Dotmatics' investment in BioGlyph gives us financial resources,
leadership, and technical expertise to accelerate the development
of our BioGlyph Platform," said McClain
Kressman, founder of BioGlyph. "We are eager to harness the
power of AI in life sciences, providing protein engineers with
cutting-edge tools for the future."
Forward Looking Statements
This press release contains forward-looking statements that are
intended to outline our general product strategy. It is intended
for informational purposes only and speaks only as of the date the
statements are first published. It is not a commitment to deliver
any functionality and should not be relied upon for making purchase
decisions. You should not put any contractual reliance on these
statements. The development, release, and timing of any products or
capabilities remains at the sole discretion of Dotmatics.
No representation or warranty, express or implied, is provided
in relation to the fairness, accuracy, correctness, completeness or
reliability of the information, opinions or conclusions expressed
herein. Only those representations or warranties that are made in
or pursuant to one or more definitive agreements involving the
parties will have any legal effect.
About Dotmatics
Dotmatics is a leader in R&D
scientific software connecting science, data, and decision-making.
Its enterprise R&D platform and scientists' favorite
applications drive efficiency and accelerate innovation. More than
2 million scientists and 10,000 customers trust Dotmatics to help
them create a healthier, cleaner, safer world. Dotmatics is a
global team of more than 800 people dedicated to supporting its
customers in over 180 countries. Dotmatics has made 14 acquisitions
since 2017. The company's principal office is in Boston, with 14 offices and R&D teams
located around the world.
Dotmatics is backed by Insight Partners, a leading global
venture capital and private equity firm investing in high-growth
technology and software scaleup companies. Learn more about
Dotmatics, its platform, and applications including GraphPad Prism,
Geneious, SnapGene, Protein Metrics, and LabArchives
at https://www.dotmatics.com.
About BioGlyph
BioGlyph is a biotech firm specializing in Multispecific
Antibody research and development. With a focus on innovative
therapeutic applications, BioGlyph leverages advanced technologies
to design and produce highly specific antibodies that address
complex biological challenges.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dotmatics-announces-investment-in-bioglyph-for-designing-registering-and-modeling-multispecific-antibodies-302214586.html
SOURCE Dotmatics Inc